Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: A multicenter survey in 30 patients

Annals of Hematology

Volumn 90, Issue 9, 2011, Pages 1083-1091

  Fiegl, Michael ^a   Falkner, Florian ^a   Steurer, Michael ^a   Zojer, Niklas ^b   Hopfinger, Georg ^c   Haslbauer, Ferdinand ^c   Winder, Guntram ^c   Voskova, Daniela ^d   Andel, Johannes ^c   Lang, Alois ^c   Brychtova, Yvona ^e   Mayer, Jiri ^e   Greil, Richard ^f   Gastl, Günther ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b WILHELMINEN HOSPITAL   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d KEPLER UNIVERSITY HOSPITAL   (Austria)

^e MASARYK UNIVERSITY   (Czech Republic)

^f UNIVERSITY OF SALZBURG   (Austria)

Author keywords

Alemtuzumab; Chronic lymphocytic leukemia; CLL; Retreatment; Retrospective survey

Indexed keywords

ALEMTUZUMAB; DEXAMETHASONE; HEMOGLOBIN; RITUXIMAB;

ADULT; AGED; B CELL LEUKEMIA; CANCER GROWTH; CANCER SURVIVAL; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCARDITIS; FEMALE; FEVER; HUMAN; INFECTION; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RETREATMENT; RETROSPECTIVE STUDY; REVIEW; SEPTICEMIA; SINUSITIS; SURVIVAL TIME; THROMBOCYTOPENIA;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; COHORT STUDIES; DATA COLLECTION; DISEASE PROGRESSION; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; RETREATMENT; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 80052359492     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-011-1192-5     Document Type: Review

References (34)

1. Hallek M, Fingerle-Rowson G, Fink AM, et al. (2009) First-line treatment with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of An International Group of Investigators and the German CLL Study Group. Blood 114: (Abstr 535)
2. T Robak A Dmoszynska P Solal-Céligny, et al. 2010 Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia J Clin Oncol 28 1756 1765 20194844 10.1200/JCO.2009.26.4556 1:CAS:528:DC%2BC3cXmtVyhurc%3D
3. B Eichhorst V Goede M Hallek 2009 Treatment of elderly patients with chronic lymphocytic leukemia Leuk Lymphoma 50 171 178 19197731 10.1080/10428190802688517 1:CAS:528:DC%2BD1MXltVaitbg%3D
4. P Hillmen AB Skotnicki T Robak, et al. 2007 Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia J Clin Oncol 25 5616 5623 17984186 10.1200/JCO.2007.12.9098 1:CAS:528:DC%2BD1cXmsFKltQ%3D%3D
5. B Eichhorst M Hallek M Dreyling ESMO Guidelines Working Group 2009 Chronic lymphocytic leukemia: ESMO minimum clinical recommendations for diagnosis, treatment and follow-up Ann Oncol 20 Suppl 4 102 104 19454423
6. A Osterborg MJ Dyer D Bunjes, et al. 1997 Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1 H treatment in chronic lymphocytic leukemia J Clin Oncol 15 1567 1574 9193354 1:STN:280:DyaK2szjs1KjtQ%3D%3D (Pubitemid 27167394)
7. KR Rai CE Freter RJ Mercier, et al. 2002 Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine J Clin Oncol 20 3891 3897 12228210 10.1200/JCO.2002.06.119 1:CAS:528: DC%2BD38XntVynsL0%3D
8. MJ Keating I Flinn V Jain, et al. 2002 Therapeutic role of alemtuzumab (Campath-1 H) in patients who have failed fludarabine: results of a large international study Blood 99 3554 3561 11986207 10.1182/blood.V99.10.3554 1:CAS:528:DC%2BD38XjvVGns7o%3D (Pubitemid 34534522)
9. P Moreton B Kennedy G Lucas, et al. 2005 Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival J Clin Oncol 23 2971 2979 15738539 10.1200/JCO.2005.04.021 1:CAS:528:DC%2BD2MXkslGhu78%3D (Pubitemid 46224116)
10. S Stilgenbauer T Zenz D Winkler, et al. 2009 Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group J Clin Oncol 27 3994 4001 19597025 10.1200/JCO.2008.21.1128 1:CAS:528:DC%2BD1MXhtFCgsbrK
11. A Cortelezzi MC Pasquini A Gardellini, et al. 2009 Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study Leukemia 23 2027 2033 19641526 10.1038/leu.2009.148 1:CAS:528:DC%2BD1MXhtl2hsrjM
12. J Lundin E Kimby M Bjorkholm, et al. 2002 Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1 H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL) Blood 100 768 773 12130484 10.1182/blood-2002-01-0159 1:CAS:528:DC%2BD38XlvVCltrg%3D (Pubitemid 34832599)
13. M Fiegl A Falkner G Hopfinger Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia, et al. 2006 Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria Cancer 107 2408 2416 17054106 10.1002/cncr.22263 1:CAS:528:DC%2BD28XhtlantLrN (Pubitemid 44748524)
14. M Fiegl G Gastl G Hopfinger, et al. 2008 Alemtuzumab in chronic lymphocytic leukaemia, other lymphoproliferative disease and autoimmune disorders Memo 1 211 222 10.1007/s12254-008-0064-8
15. M Fiegl M Erdel I Tinhofer, et al. 2010 Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories Ann Oncol 21 12 2410 2419 20466745 10.1093/annonc/mdq236 1:STN:280:DC%2BC3M%2FgvFCgsQ%3D%3D
16. K Rieger U Von Grünhagen T Fietz, et al. 2004 Efficacy and tolerability of alemtuzumab (CAMPATH-1 H) in the salvage treatment of B-cell chronic lymphocytic leukemia-change of regimen needed? Leuk Lymphoma 45 345 349 15101722 10.1080/10428190310001598017 1:CAS:528:DC%2BD3sXptVOgt7w%3D (Pubitemid 38181439)
17. Eyged M, Kollar B, Karadi E et al. (2007) Fifth succesfully retreatment with Alemtuzumab in patient with chronic lymphocytic leukemia. Blood 110 (Abstr 4713)
18. D Hui W Lam C Toze, et al. 2008 Alemtuzumab in clinical practice: a British Columbia experience Leuk Lymphoma 49 218 226 18231907 10.1080/10428190701760029 1:CAS:528:DC%2BD1cXhtFekurw%3D (Pubitemid 351193914)
19. Thieblemont C, Bouafia F, Antal D et al. (2003) Feasibility of Alemtuzumab re-treatment in heavily pretreated refractory B-CLL/SLL. Blood 102 (Abstr 5165)
20. A Osterborg R Foà RF Bezares, et al. 2009 Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia Leukemia 23 1980 1988 19626051 10.1038/leu.2009.146 1:STN:280:DC%2BD1MjltFSrsw%3D%3D
21. BD Cheson JM Bennett M Grever, et al. 1996 National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment Blood 87 4990 4997 8652811 1:CAS:528:DyaK28XjsFGisb8%3D (Pubitemid 26189840)
22. CE Dearden E Matutes B Cazin, et al. 2001 High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1 H Blood 98 1721 1726 11535503 10.1182/blood.V98.6.1721 1:CAS:528:DC%2BD3MXntFWgsb8%3D
23. M Leporrier 2004 Role of fludarabine as monotherapy in the treatment of chronic lymphocytic leukemia Hematol J 5 Suppl 1 S10 S19 15079149 10.1038/sj.thj.6200387 1:CAS:528:DC%2BD2cXjtVSgs7o%3D (Pubitemid 38744816)
24. G Juliusson J Liliemark 1994 Retreatment of chronic lymphocytic leukemia with 2-chlorodeoxyadenosine (CdA) at relapse following CdA-induced remission: no acquired resistance Leuk Lymphoma 13 75 80 8025525 10.3109/10428199409051654 1:STN:280:DyaK2c3pslGguw%3D%3D (Pubitemid 24122129)
25. B Lemieux F Bouafia C Thieblemont, et al. 2004 Second treatment with rituximab in B-cell non-Hodgkin's lymphoma: efficacy and toxicity on 41 patients treated at CHU-Lyon Sud Hematol J 5 467 471 15570286 10.1038/sj.thj.6200559 1:CAS:528:DC%2BD2cXhtVagtr3M (Pubitemid 40045278)
26. R Sood H Carloss R Kerr, et al. 2009 Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib Am J Hematol 84 657 660 19731393 10.1002/ajh.21517 1:CAS:528:DC%2BD1MXhtlyqsLnJ
27. Petrucci MT, Blau IW, Corradini P, et al. (2009) Efficacy and Safety of Retreatment with Bortezomib in Patients with Multiple Myeloma: Interim Results From RETRIEVE, a Prospective International Phase 2 Study. Blood 114 (Abstr 3866)
28. TT Nguyen JD Wright MA Powell, et al. 2008 Prognostic factors associated with response in platinum retreatment of platinum-resistant ovarian cancer Int J Gynecol Cancer 18 1194 1199 18217964 10.1111/j.1525-1438.2007.01184.x 1:STN:280:DC%2BD1M%2FptFOmsA%3D%3D
29. EF Smit SA Burgers B Biesma, et al. 2009 Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer J Clin Oncol 27 2038 2045 19307503 10.1200/JCO.2008.19.1650 1:CAS:528:DC%2BD1MXls1CgtLY%3D
30. Fiegl M, Falkner F, Falkner A, et al. (2007) Retreatment with alemtuzumab after a first, successful alemtuzumab treatment in B-CLL. Blood 110(Abstr 4714)
31. H Döhner S Stilgenbauer A Benner, et al. 2000 Genomic aberrations and survival in chronic lymphocytic leukemia New Engl J Med 343 1910 1916 11136261 10.1056/NEJM200012283432602 (Pubitemid 32064784)
32. I Tinhofer M Steurer G Leitinger, et al. 2006 The effect of IgVH mutational status on the induction of apoptosis by rituximab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: evidence from a clinical phase I/II trial Haematologica 91 1291 1293 16956841 1:CAS:528: DC%2BD28XhtVOhtL3O (Pubitemid 44408452)
33. N Gupta S Kavuru D Patel, et al. 2002 Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia Leukemia 16 2092 2095 12357362 10.1038/sj.leu.2402676 1:CAS:528: DC%2BD38XnsVamsLg%3D (Pubitemid 35203453)
34. A Younes J Romaguera O Mesina, et al. 1998 Paclitaxel plus high-dose cyclophosphamide with G-CSF support in patients with relapsed and refractory aggressive non-Hodgkin's lymphoma Br J Haematol 103 678 683 9858216 10.1046/j.1365-2141.1998.01048.x 1:CAS:528:DyaK1MXhslKhsw%3D%3D (Pubitemid 28545301)